7 Literaturverzeichnis

1. Abbott WM, Green RM, Matsumoto T, et al. Prosthetic above-knee femoral-popliteal bypass: indications and choice of graft. Semin Vasc Surg 1997; 10: 3-7.
2. Adhoute G, Andreassian B, Boccalon H, et al. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: Results after 6 month of a controlled multicenter study. J Cardiovasc Pharmacol 1990; 16 (Suppl 3): 75-80.
3. Ahmadi R, Schillinger M, Maca T, Minar E. Femoropopliteal arteries: Immediate and long-term results with a Dacron-covered stent-graft. Radiology 2002; 223: 345-350.
4. Allen BT, Reilly JM, Rubin BG, et al. Femoropopliteal bypass for claudication: vein vs. PTFE. Ann Vasc Surg 1996; 10: 178-185.
5. Anonym. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
6. Anonym. Die CLASSIC-Studie: Clopidogrel + ASS versus Ticlopidin + ASS bei Stent-Patienten. Z Kardiol 1999; 88 (Suppl 5): 1-4.
7. Anonym. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Concensus (TASC). Eur J Vasc Endovasc Surg 2000; 19 (Suppl A): S144-243.
8. Anonym. VIBRANT-Study. Medical Customer Service, W.L. Gore&Associates, Inc. 2006-08-28
9. Ansel GM, Sample NS, Botti CF, et al. Cutting balloon angioplasty of the popliteal and infrapopliteal vessels for symptomatic limb ischemia. Catheter Cardiovasc Interv 2004; 61: 1-4.
10. Archie JP jr. Femoropopliteal bypass with either adequate ipsila-teral reversed saphenous vein or obligatory polytetrafluoroethylene. Ann Vasc Surg 1994; 8: 475-484.

11. Ariyoshi H, Okuyama M, Okahara K, et al. Expended polytetrafluoroethylene (ePTFE) vascular graft loses its thrombogenicity six months after implantation. Thromb Res 1997; 88: 427-433.

12. Bauermeister G. Endovascular stent-grafting in the treatment of superficial femoral artery occlusive disease. J Endovasc Ther 2001; 8: 315-320.

13. Becquemin JP, Favre JP, Marzelle J, Nemoz C, Corsin C, Leizorovicz A. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg 2003; 37: 487-494.

14. Bergqvist D, Troeng T, Elfstrom J, et al. Auditing surgical outcome: ten years with the Swedish Vascular Registry (SWED-VASC). The Steering Commettee of Swedvasc. Eur J Surg 1998; 164 (Suppl 581): 3-8.

15. Binaghi F, Fronteddu PF, Carboni MR, Onnis A, Astara C, Pitzus F. Evaluation of non-invasive haemodynamic parameters in patients with intermittent claudication subjected to physical training. Int Angiol 1990; 9: 251-255.

16. Bisler H. Klinische Erfolge der Buflomediltherapie bei arterieller Verschlußkrankheit. Therapiewoche 1983; 33: 2204-2208.

17. Blume J. Klinische Wirksamkeit der intraarteriellen Infusionstherapie mit Prostaglandin E_1 im Stadium II b der arteriellen Verschlußkrankheit. Therapiewoche 1987; 37: 4819-4823.

18. Bolia A, Brennan J, Bell PR. Recanalisation of femoro-popliteal occlusions: improving success rate by subintimal recanalisation (letter). Clin Radiol 1989; 40: 325.

19. Bollinger A. Funktionelle Angiologie. Thieme, Stuttgart 1979.

20. Brambilla N, Laudisa M, Llambro M. Cryoplasty in the treatment of iliac and superficial femoral disease (abstract). J Cardiovasc Surg 2004; 45 (Suppl 1-3): 12.

21. Bray PJ, Robson WJ, Bray AE. Percutaneous treatment of long superficial femoral artery occlusive disease:efficacy of the Hemobahn stentgraft. J Endovasc Ther 2003; 10: 619-628.

22. Cachovan M. Physikalische Therapie. In: Rieger H, Schoop W, Hrsg. Klinische Angiologie. Berlin/Heidelberg/New York: Springer, 1998: 230-238.

23. Cachovan M, de Marées H, Kunitsch G. Einfluß von Intervalltraining auf die Leistungsfähigkeit und periphere Durchblutung bei Patienten mit Claudicatio intermittens. Z Kardiol 1976; 65: 54-67.

24. Cejna M, Illiasch H, Waldenberg P, Horvath W, Thurnber SA, Lammer J. PTA vs. Palmaz stent in femoropopliteal obstructions: a prospective randomized trial - long term results. Radiology 1998; 209: 492-495.

25. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent in femoropopliteal obstructions: a multicenter prospective randomised study. J Vasc Interv Radiol 2001; 12: 23-31.

26. Clark TWI, Groffsky JL, Soulen MC. Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry. J Vasc Interv Radiol 2001; 12: 923-933.

27. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol 1989; 14 (Suppl 6): S12-15.

28. Conroy RM, Gordon IL, Tobis JM, et al. Angioplasty and stent placement in chronic occlusion of the superficial femoral artery: technique and results. J Vasc Interv Radiol 2000; 11: 1009-1020.

29. Cossman DV, Ellison JE, Wagner WH, Carroll RM. Comparison of contrast angiography to arterial mapping with color-flow duplex imaging in the lower extremities. J Vasc Surg 1989; 10: 522-529.

30. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386.

31. Daenens K, Maleux G, Fourneau J, Nevelsteen A. Hemobahn stent-grafts in the treatment of femoropopliteal occlusive disease. J Cardiovasc Surg 2005; 46: 25-29.

32. Dahllöf AG, Björntorp P, Holm J, Schersten T. Metabolic activity of skeletal muscle in patients with peripheral arterial insufficiency. Effect of physical training. Eur J Clin Invest 1974; 4: 9-15.

33. Deutsche Gesellschaft für Angiologie, Gesellschaft für Gefäßmedizin. Leitlinien zur Diagnostik und Therapie der arteriellen Verschlusskrankheit der Becken-Beinarterien. VASA 2001; Suppl 57: 30.

34. Deutschmann HA, Schedlbauer P, Berczi V, Portugaller H, Tauss J, Hausegger K. Placement of Hemobahn stent-grafts in femoropopliteal arteries: early experience and midterm results in 18 patients. J Vasc Interv Radiol 2001; 12: 943-950.

35. Diamantopoulos EJ, Grammostianous CS, Stavreas NP, Raptis SA, Moulopoulos SD. Buflomedil bei Diabetikern mit Claudicatio intermittens – eine plazebokontrollierte Studie. In: Messmer K, Hrsg: Ischämische Gefäßerkrankung und Mikrozirkulation. München: Zuckschwerdt, 1989: 85-96.

36. Diehm C. Doppelblinde placebokontrollierte Studie zur ambulanten intravenösen PGE1-Therapie im Stadium IIb. VASA 1994; Suppl 43: 90-93.

37. Diehm C, Trampisch H-J, Lange S, et al. Ergebnisse der getABI-Studie: Hohe 1-Jahres-Mortalität bei Patienten mit peripherer arterieller Verschlusskrankheit. Cardiovasc 2004; 4: 23-28.

38. Donaldson MC, Mannick JA, Whittemore AD. Femoral-distal bypass with in situ greater saphenous vein: Long-term results using the mills valvulotome. Ann Surg 1991; 213: 457-465.

39. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Circulation 1964; 30: 654-670.

40. Duda S, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: The SIROCCO II Trial. J Vasc Interv Radiol 2005; 16: 331-338.

41. Duda S, Bosiers M, Pusich B, et al. Endovascular treatment of peripheral artery disease with expanded PTFE-covered nitinol stents: interim analysis from a prospective controlled study. Cardiovasc Intervent Radiol 2002; 25: 413-418.

42. Duda S, Poerner T, Wiesinger B, Rundback G, Wiskirchen J, Haase K. Drug-eluting stents: potential applications for peripheral arterial occlusive disease. J Vasc Interv Radiol 2003; 14: 291-301.

43. Duda S, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease. Circulation 2002; 106: 1505-1509.

44. Edelman RR. Basic principles of magnetic resonance angiography. Cardiovasc Intervent Radiol 1992; 15: 3-13.

45. Ekroth R, Dahllöf AG, Gundevall B, Holm J, Schersten T. Physical training of patients with intermittent claudication: Indications, methods and results. Surgery 1978; 84: 640-643.

46. Fahrig C, Heidrich H. Ambulanter Gefäßsport – unverzichtbares Therapieangebot oder sinnlose Turnerei. VASA 2000; (Suppl 56): 43-49.

47. Fava M, Loyola S, Polydotou A, et al. Cryoplasty for femoropopliteal arterial disease: late angiographic results of initial human experience. J Vasc Interv Radiol 2004; 15: 1239-1243.

48. Fillinger MF, Reinitz ER, Schwartz RA, et al. Graft geometry and venous intimal-medial hyperplasia in arteriovenous loop grafts. J Vasc Surg 1990; 11: 556-566.

49. Frank D. Die Katheter-Rekanalisation langer Verschlüsse der femoro-poplitealen Gefäßachse. VASA 2000; (Suppl 56): 57-64.

50. Geraghty PJ. Covered stenting of the superficial artery using the Viabahn stent-graft. Perspect Vasc Surg Endovasc Ther 2006; 18: 39-45.

51. Gillings D, Koch G, Reich T, Stager WJ. Another look at the pentoxifylline efficacy data for intermittent claudication. J Clin Pharmacol 1987; 27: 601-609.

52. Gordon IL, Conroy RM, Arefi M, et al. Three-year outcome of endovascular treatment of superficial femoral artery occlusion. Arch Surg 2001; 136: 221-228.

53. Gröchenig E. Gefäßmedizin. Berlin: ABW Wissenschaftsverlag, 2002.

54. Grüntzig A, Hopff H. Perkutane Rekanalisation chronischer arterieller Verschlüsse mit einem neuen Dilatationskatheter. Dtsch Med Wschr 1974; 99: 2502-2505.

55. Hagenaars T, Gussenhoven EJ, Smeets L, et al. Midterm follow-up of ballon-expandable ePTFE endografts in the femoropopliteal segment. J Endovasc Ther 2002; 9: 428-435.

56. Hamann H, Krawczynski H, Mayer W, et al. Der supragenuale femoropopliteale Bypass – Vene vs. Gefäßprothese. Gefäßchirurgie 1998; 3: 14-19.

57. Hartung O, Otero A, Dubuc M, et al. Efficacy of Hemobahn in the treatment of superficial femoral artery lesions in patients with acute or critical ischemia: a comparative study with claudicants. Eur J Vasc Endovasc Surg 2005; 30: 300-306.

58. Henry M, Amor M, Cragg A, et al. Occlusive and aneurysmal peripheral arterial disease: assessment of a stent-graft system. Radiology 1996; 201: 717-724.

59. Henry M, Amor M, Ethévenot G, et al. Initial experience with the Cragg Endopro System 1 for intraluminal treatment of peripheral vascular disease (abstract). J Endovasc Ther 1994; 1: 31-43.

60. Henry M, Amor M, Ethevenot G, Henry I. Palmaz stent placement in iliac and femoropopliteal stenoses: primary and secondary patency in 319 patients with 2-4 year follow-up. Radiology 1995; 197: 167-174.

61. Henry M, Henry I, Klonaris C, Hugel M. Clinical experience with the OptiMed Sinus Stent in the peripheral arteries. J Endovasc Ther 2003; 10: 772-779.

62. Hepp W, von Bary S, Corovic D, et al. Therapeutic efficacy of intravenous prostaglandin E1 versus pentoxifylline in patients with intermittent claudication. In: Diehm C, Sinzinger H, Rogatti W, Hrsg. Prostaglandin E_1 – new aspects on pharmacology, metabolism and clinical efficacy. Berlin/Heidelberg/New York/Tokyo: Springer, 1991: 101-108.

63. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart 2003; 89: 651-656.

64. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness and treatment in primary care. JAMA 2001; 286: 1317-1324.

65. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart,

Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006; 47: 1239-1312.

66. Hofmann M, Farber A, Fischer M, Wilde J. Stent-Graft-Implantation in der Femoralis superficialis - Ein erfolgversprechender Thearpieansatz? Gefäßchirurgie 2001; 6: 25-29.

67. Hunink MGM, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J, Harrington DP. Revascularization for femoropopliteal disease: a decision and cost-effectiveness analysis. JAMA 1995; 274: 165-171.

68. Hynes N, Akhtar Y, Manning B, et al. Subintimal angioplasty as a primary modality in the management of critical limb ischemia: comparison to bypass grafting for aortoiliac and femoropopliteal occlusive disease. J Endovasc Ther 2004; 11: 460-471.

69. Jahnke T, Andresen R, Müller-Hülsbeck S, et al. Hemobahn stent-grafts for treatment of femoropopliteal arterial obstructions: Midterm results of a prospective trial (abstract) J Vasc Interv Radiol 2003; 14: 41-51.

70. Jahnke T, Voshage G, Müller-Huelsbeck S, Grimm J, Heller M, Brossmann J. Endovascular placement of self-expanding Nitinol Coil Stents for treatment of femoropopliteal obstructive disease. J Vasc Interv Radiol 2002; 13: 257-266.

71. Janasson T, Ringquist I. Effect of training on the post-exercise ankle blood pressure reaction in patients with intermittent claudication. Clin Physiol 1987; 7: 63-69.

72. Jeans WD, Armstrong S, Cole SEA, Horrocks M, Baird RN. Fate of patients undergoing transluminal angioplasty for lower limb ischaemia. Radiology 1990; 177: 559-564.

73. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985; 33: 13-17.

74. Karnik R. Effects of naftidrofuryl in patients with intermittent claudication. Angiology 1988; 39: 234-240.

75. Katzenschlager R, Ahmadi A, Minar E, et al. Femoropopliteal artery: initial and 6-month results of color duplex US-guided percutaneous transluminal angioplasty. Radiology 1996; 199: 331-334.

76. Kent KC, Donaldson MC, Attinger CE. Femoropopliteal reconstruction for claudication. The risk of life and limb. Arch Surg 1988; 123: 1196-1198.

77. Kram HB, Gupta SK, Veith FJ, Wengerter KR, Panetta TF, Nwosisi C. Late results of two hundred seventeen femoropopliteal bypasses to isolated popliteal artery segments. J Vasc Surg 1991; 14: 386-390.

78. Kriessmann A, Neiss A. Klinischer Wirksamkeitsnachweis von Naftidrofuryl bei Claudicatio intermittens. VASA 1988; (Suppl 24): 27-32.

79. Laird JR. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popli-teal arteries. J Endovasc Ther 2006; 13 (Suppl II): II30-II40.

80. Laird JR, Biamino G, McNamara T, et al. Cryoplasty for the treatment of femoropopliteal arterial disease: extended follow-up results. J Endovasc Ther 2006; 13 (Suppl II): II-52-II-59.

81. Lammer J, Dake MD, Bleyn J, et al. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. International Trial Study Group. Radiology 2000; 217: 95-104.

82. Lawrence JA, Kim D, Kent KC, Stehling MK, Rosen MP, Raptopoulos V. Lower extremity spiral CT angiography versus catheter angiography. Radiology 1995; 194: 903-908.

83. Lazaris A, Tsiamis A, Fishwick G, Bolia A, Bell P. Clinical outcome of primary infrainguinal subintimal angioplasty in diabetic patients with critical lower limb ischemia. J Endovasc Ther 2004; 11: 447-453.

84. Leseche G, Ohan J, Bouttier S, Palombi T, Bertrand P, Andreassian B. Above-knee femoropopliteal bypass grafting using endothelial cell seeded PTFE grafts: five-year clinical experience. Ann Vasc Surg 1995; 9 (Suppl): S15-23.

85. Lindgärde F, Jelnes R, Björkman H, et al. Conservative drug treatment in patients with mo-derate severe chronic occlusive peripheral arterial disease. Circulation 1989; 80: 1549-1556.

86. Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith A. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow-up. Radiology 2002; 222: 37-43.

87. Lyden SP, Shimshak TM. Contemporary endovascular treatment for disease of the superficial femoral and popliteal arteries: An integrated device-based strategy. J Endovasc Ther 2006; 13 (Suppl II): II-41-II-51.

88. Maas U, Cachovan M, Alexander K. Einfluß eines Intervalltrainings auf Gehstrekke, Hämodynamik und Ventilation bei Patienten mit Claudicatio intermittens. I. Änderung der Gehstrecke. VASA 1982; 11: 91-96.

89. Maini BS, Orr R, O´Mara P, Hendershott T. Outcomes and resource utilization in a managed care setting for lower extremity vein bypass grafts. Am J Surg 1996; 172: 113-117.

90. Mannarino E, Pasqualini L, Innocente S, Scricciolo V, Riganese A, Ciuffetti G. Physical training and antiplatelet treatment in stage II peripheral arterial occlusive disease: alone or combined? Angiology 42: 513-521.

91. Marzelle J, Fichelle JM, Alimi G, et al. Revascularisations femoro-distales pour ischemie chronique „critique“ d´origine atheromateuse. 695 observations. Presse Med 1992; 15: 253-257.

92. Matsi PJ, Manninen HI, Vanninen RL, et al. Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1–3-year follow-up. Radiology 1994; 191: 727-733.

93. Mewissen MW. Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Tech Vasc Interv Radiol 2004; 7: 2-5.

94. Moneta GL, Yeager RA, Antonovie R. Accuracy of lower extremity arterial duplex mapping. J Vasc Surg 1992; 15: 275-284.

95. Moody AP, Khaffaf HS, Lehert P, Harris PL, Charlesworth D. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994; 23 (Suppl 3): 44-47.

96. Mulligan SA, Matsuda T, Lanzer P, Gross GM. Peripheral artery occlusive disease: Prospective comparison of MR angiography and color duplex US with conventional angiography. Radiology 1991; 178: 695-700.

97. Ohki T. SFA disease: facing reality. Endovascular Today 2005; 6: 47-48.

98. Ohki T, Marin ML, Veith FJ, et al. Anastomotic intimal hyperplasia: a comparison between conventional anfd endovascular stent graft techniques. J Surg Res 1997; 69: 255-267.

99. Patterson RB, Fowl RJ, Kempczinski RF. Preferential use of PTFE of above-knee femoropopliteal bypass grafts. Ann Vasc Surg 1990; 4: 338-343.

100. Porstmann W. Ein neuer Korsett-Ballonkatheter zur transluminalen Rekanalisation nach Dotter unter besonderer Berücksichtigung von Obliterationen an den Beckenarterien. Radiol Diagn (Berlin) 1973; 14: 239-242.

101. Porter JM, Culer B, Lee B, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104: 66-72.

102. Prendiville EJ, Yeager A, O´Donnell E. Long-term results with the above-knee popliteal expanded PTFE-graft. J Vas Surg 1990; 11: 517-524.

103. Rabbi JF, Kiran RP, Gersten G. Early results with infrainguinal cutting balloon angioplasty limits distal dissection. Ann Vasc Surg 2004; 18: 640-643.

104. Raithel D. Role of PTFE grafts in infrainguinal arterial reconstructions. In: Veith J, Hrsg. Current critical problems in vascular surgery, Vol. 3. St. Louis: Quality Medical Publishing, 1991: 66-72.

105. Raithel D. Gefäßchirurgische Verfahren. In: Rieger H, Schoop W, Hrsg. Klinische Angiologie. Berlin/Heidelberg/New York: Springer, 1998: 356-367.

106. Rashid SN, Clark HG, Vann RD, Gerth WA, Palmos LA, Mikat EM. The effect of interstitial air on the in vitro thrombogenicity of ePTFE vascular grafts. J Bioact Compat Polym 1992; 7:54-64.

107. Rosenthal D, Evans RD, McKinsey J, et al. Prosthetic above-knee femoropopliteal bypass for intermittent claudication. J Cardiovasc Surg Torino 1990; 31: 462-468.

108. Rosetzsky A, Struckmann J, Mathiesen FR. Minimal walking distance following exercise treatment in patients with arterial occlusive disease. Ann Chir Gynaecol 1985; 74: 261-264.

109. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 369-377, 420-425.

110. Rudofsky G. Intravenöse PGE1-Infusionsbehandlung bei Patienten mit arterieller Verschlußkrankheit im Stadium II b. In: Heidrich H, Böhme H, Rogatti W, Hrsg. Prostaglandin E_1-Wirkungen und therapeutische Wirksamkeit. Berlin/Heidelberg/ New York: Springer, 1988, 103-111.

111. Rudofsky G, Altenhoff B, Meyer P, Lohmann A. Intraarterial perfusion with prostaglandin E1 in patients with intermittent claudication. VASA 1987; 17 (Suppl): 47-51.

112. Rudofsky G, Haussler F, Künkel HP, et al. Zur intravenösen Pentoxifyllin-Behandlung der chronischen peripheren arteriellen Verschlußkrankheit. Med Welt 1988; 39: 1136-1140.

113. Rutherford R, Becker G. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. Radiology 1991; 181: 277-281.

114. Sabeti S, Mlekusch W, Amighi J, et al. Primary patency of long-segment self-expanding nitinol stents in the femoropopli-teal arteries. J Endovasc Ther 2005; 12: 6-12.

115. Saloner D. An introduction to MR angiography. Radiographics 1995; 15: 435-465.

116. Sapoval MR, Long AL, Raynaud AC, Beyssen BM, Fiessinger JN, Gaux JC. Femoropopliteal stent placement: Long-term results. Radiology 1992; 184: 833-839.

117. Saxon RR, Coffman JM, Gooding JM, Natuzzi E, Ponec DJ. Long-term results of ePTFE stent-graft versus angioplasty in the femoropopli-teal artery: single center experience from a prospective, randomized trial. J Vasc Interv Radiol 2003; 14: 303-311.

118. Scheffler P, Hamette D, Müller H. Gezieltes Gefäßtraining bei pAVK II b: Additiver Effekt von i.v. PGE_1 versus i.v. Pentoxifyllin während des Trainings. VASA 1991; (Suppl 33): 350-353.

119. Scheinert D, Biamino G. Femoropopliteal occlusions: experience with peripheral excimer laser angioplasty. Curr Interv Cardiol Rep 2001; 3: 130-138.

120. Schillinger M, Exner M, Mlekusch W, et al. Balloon angioplasty and stent implantation induce a vascular inflammatory reaction. J Endovasc Ther 2002; 9: 59-66.

121. Schlager O, Dick P, Sabeti S, et al. Long-segment SFA stenting - the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther 2005; 12: 676-684.

122. Schneider E, Grüntzig A, Bollinger A. Spätergebnisse der PTA im unteren Extremitätenbereich. VASA 1982; 11: 336-339.

123. Schrör K. Prostaglandine und Atherosklerose. In: Heidrich H, Böhme H, Rogatti W, Hrsg. Prostaglandin E_1 – Wirkungen und therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988: 3-13.

124. Selvin E, Erlinger Th. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110: 738-743.

125. Sinzinger H. Allgemeine Stadieneinteilung, Ätiologie und Pathogenese der Arteriosklerose. In: Rieger H, Schoop W, Hrsg. Klinische Angiologie. Berlin/Heidelberg/New York: Springer, 1998: 35-46.

126. Strauss AL, Sandor D, Karasch G. Vergleich der Farbduplexsonographie mit der arteriellen Angiographie (abstract). Bildgebung/Imaging 1994; 61 (Suppl 2): 35.

127. Strecker EP, Boos IB, Gottmann D. Femoropopliteal artery stent placement: evaluation of long-term success. Radiology 1997; 205: 375-383.

128. Taylor LM, Porter JM. Clinical and anatomic considerations for surgery in femoropopliteal disease and the results of surgery. Circulation 1991; 83 (Suppl 2): 63-69.

129. The Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet 2000, 335: 346-351.

130. Trübestein G, Balzer K, Bisler H, et al. Buflomedil bei arterieller Verschlußkrankheit. Ergebnisse einer kontrollierten Studie. Dtsch Med Wochenschr 1982; 107: 1957-1962.

131. Virmani R, Kolodgie FD, Dake MD, et al. Histopathologic evaluation of an expanded polytetrafluoroethylene-nitinol stent endoprothesis in canine iliofemoral arteries. J Vasc Interv Radiol 1999; 10: 445-456.

132. Vogel TR, Shindelman LE, Nackman GB, et al. Efficacious use of nitinol stents in teh femoral and popliteal arteries. J Vasc Surg 2003; 38: 1178-1184.

133. Vroegindeweij D, Tielbeek AV, Buth J, Vos LD, van den Bosch HC. Directional atherectomy versus balloon angioplasty in segmental femoropopliteal artery disease: two-year follow-up with color-flow duplex scanning. J Vasc Surg 1995; 21: 255-269.

134. Wahlgren CM, Kalin B, Lund K, Swedenborg J, Takolander R. Long-term outcome of infrainguinal percutaneous transluminal angioplasty. J Endovasc Ther 2004; 11: 284-293.

135. Wallner B. MR-Angiography. Stuttgart/New York: Thieme, 1993.

136. Wiesinger B, Beregi JP, Oliva VL, et al. PTFE-covered self-expanding nitinol stents for the treatment of severe iliac and femoral artery stenoses and occlusions: Final results from a prospective Study. J Endovasc Ther 2005; 12: 240-246.

137. Wissgott C, Scheinert D, Rademeker J, Werk M, Schedel H, Steinkamp HJ. Treatment of long superficial femoral artery occlusions with excimer laser angioplasty: long-term results after 48 months. Acta Radiol 2004; 45: 23-29.

138. Yilmaz S, Sindel T, Yegin A, Lüleci E. Subintimal angioplasty of long superficial femoral artery occlusions (abstract). J Vasc Interv Radiol 2003; 14: 997-1010.

139. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.

140. Zehnder T, von Briel C, Baumgartner I, et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. J Endovasc Ther 2003; 10: 304-311.

141. Zeller T, Frank U, Bürgelin K, et al. Early experiences with a rotational thrombectomy device for treatment of acute subacute infra-aortic arterialocclusions. J Endovasc Ther 2003; 10: 322-331.

142. Zeller T, Rastan A, Schwarzwaelder U, et al. Percutaneous peripheral atherectomy of femoropopliteal stenoses using a new generation device: six-month results from a single-center experience. J Endovasc Ther 2004; 11: 676-685.

143. Zempo N, Esato K, O´Hara M, Fujioka K, Kuga T, Takenaka H. Is the preferential use of polytetrafluoroethylene grafts for below-knee femoropopliteal bypass justified? Int Surg 1993; 78: 162-165.

144. Z´graggen K, Inderbitzi R, Krebs T, Stirnemann P. Die Wertigkeit der supragenikularen femoro-poplitealen Polytetrafluoroethylen-Prothese in der chirurgischen Behandlung der chronisch-arteriellen Verschlußkrankheit. VASA 1990; 19: 311-314.